AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05079828 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 68Ga-PSMA-11
Description: PET/CT scan using 68Ga-PSMA-11
Study NCT05939362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI follow-up
Description: MRI follow-up for patient with early onset Alzheimer's disease
Study NCT05287828 — intervention group
Intervention type: OTHER
Intervention: Surgeons CT scan analysis
Description: Surgeons extract indicators using standard methods of analysis
Study NCT05287828 — intervention group
Intervention type: DEVICE
Intervention: PRAEVAorta CT scan analysis
Description: CT scans are analysed using PRAEVAorta Suite which is composed of the software PRAEVAorta 2 and PRAEVAorta Web. Indicators extraction is fully automatic.
Study NCT04709575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5715
Description: Administered subcutaneously
Study NCT04709575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo that replaces REGN5713-5714-5715
Study NCT05283252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3-D printed Guide
Description: Guided Endodontic micro-surgery
Study NCT05283252 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Endodontic Micro-Surgery
Description: Free-hand endodontic micro-surgery
Study NCT06476223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artificial saliva containing cumin and ginger extract
Description: The sample will be sprayed 2 puff/time, 3 times/day, for 14 days.
Study NCT06476223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The sample will be sprayed 2 puff/time, 3 times/day, for 14 days.
Study NCT05653960 — intervention group
Intervention type: OTHER
Intervention: EMR or ESD
Description: Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are two main endoscopic treatment options for colorectal neoplasms
Study NCT06193746 — intervention group
Intervention type: DEVICE
Intervention: non-invasive laser therapy
Description: (diode laser, continuous output, in skin contact mode, 0.005W,0.2cm,beam spot area 0.03cm2, 288j/cm ,1800s) in the morning session, we measured lipid profile and kidney function before and after treatment to measure improvement
Study NCT04985630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mitopure
Description: Fruit flavored sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)
Study NCT04985630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate Juice
Description: 100% Pomegranate juice
Study NCT04828668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C)
Description: Hemp seed oil
Study NCT04828668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C)
Description: Hemp seed oil
Study NCT06211751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3909 tablets
Description: TQB3909 is a protein inhibitor.
Study NCT06650085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loop ileostomy
Description: Patient undergoing anterior rectal resection will receive loop ileostomy
Study NCT06650085 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Loop colostomy
Description: Patient undergoing anterior rectal resection will receive loop colostomy
Study NCT06649786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic superior rectal mucosal ligation
Description: The patient takes the left side decubitus position, the endoscope is connected with 6 serial ligators, the cup of the sleeve is pointed at the upper edge of the straight anal line and the rectal mucosa is continuously aspirated under negative pressure. The mucosa enters the sleeve and sees a full-screen red sign. The sensing loop is successfully triggered, indicating that the loop is complete.
Study NCT06649786 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic hemorrhoid ligation
Description: The patient takes the left side decubitus position,the endoscope is connected with 6 serial ligators,the cup the sleeve is aligned with the base of the hemorrhoid (above the dentate line) for continuous negative pressure suction.The hemorrhoid enters the sleeve and sees a full-screen red sign. Turn the handle of the sleeve clockwise and feel that the loop is successfully triggered, the ligature is completed.
Study NCT06650358 — intervention group
Intervention type: DEVICE
Intervention: Light Adjustable Lens+
Description: The Light Adjustable Lens+ (LAL+) is a posterior chamber, UV absorbing, three-piece, foldable, photo reactive silicone intraocular lens with a squared-posterior optic edge intended to be implanted in the capsular bag following phacoemulsification. Selective exposure to the implanted LAL+ using the Light Delivery Device (LDD) to deliver a spatially profiled UV light produces modifications in the lens curvature resulting in a spherical or spherocylindrical power change postoperatively. A subsequent lock-in exposure is delivered to the implanted LAL+ to stabilize the lens power. The LAL+ has a modified aspheric anterior surface that creates a small continuous increase in central lens power, which is designed to slightly extend the depth of focus.
Study NCT05897931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connective tissue massage
Description: Connective Tissue Massage will be applied by starting from the lumbosacral region, continuing from the lower thoracic region, and finishing by applying it to the scapular region, interscapular region, and cervico-occipital region.
Study NCT05897931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tape Application
Description: Taping will be applied to the levator scapula and upper trapezius muscles in a Y shape, with 25% tension and while the participants were in an upright position. Again in the same position, this time the C shaped taping technique will be adhered with 50% tension from the middle fibers of the trapezium to the last rib.
Study NCT04430387 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The saliva ejector
Description: A thin suction tube that draws water, saliva, blood, and debris from the mouth to provide patient comfort, preventing patient from constantly having to sit up and spit while maintain a clear operative field. It is connected through the low-volume suction hose in the dental chair. It can be held by the dental assistant, the dental provider or by the patient. In practice, it can be also contoured and hang by the cheek of the patient due to its light weight.
Study NCT04430387 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The high-volume evacuator
Description: The high-velocity air evacuation device. It is connected through the high-volume suction hose in the dental chair. It is operated by a dental assistant during the dental treatment, owing to the challenge posed by the rigid disposable attachment and bulky high-volume suction hose.
Study NCT04430387 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The DryShield
Description: The device is attached to the high-volume suction hose to provide continuous suction of intraoral fluid and debris, and also simultaneous isolation to both maxillary and mandibular quadrants on the same side. Other advantages of these devices include retracting the tongue and cheek, and prevention of aspiration.
Study NCT05316662 — intervention group
Intervention type: DRUG
Intervention: Semaglutide
Description: Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
Study NCT06484153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Two doses of pirfenidone (200 mg,tid,po;500 mg,tid,po) were set up. Using the 3+3 design, the DLT observation period is 28 days.
Study NCT06484153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: 3mg, orally, qd
Study NCT06484153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg iv every 3 weeks
Study NCT04655716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate 150Meq/L/D5W Inj
Description: Urine alkalinisation will be performed to achieve urine pH 7.5-8.5. Urine alkalinisation will be continued for up to 10 days or until patient is discharged or until primary endpoint is reached. Urine pH will be measured at point of care by dipstick.
Study NCT04823442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: Mirabegron: a single dose of 200 mg mirabegron (4 tablets of 50 mg)
Study NCT04823442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Mirabegron: a single dose of 200 mg mirabegron (4 tablets of 50 mg)
Study NCT04823442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol Fumarate
Description: a single dose of 10 mg (2 tablets of 5 mg)
Study NCT05125406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure therapy with Virtual Reality.
Description: Experimental arm patients will be offered Exposure therapy with Virtual Reality (ETRV) support with a virtual reality headset. A scenario with progressively increasing stress levels linked to the ICU environment and different situational contexts (alarms, etc.) will be presented to patients. This habituation to the potentially anxiety context of ICU will reduce the occurrence of psycho-cognitive disorders by progressive extinction phenomenon.
Study NCT06410014 — intervention group
Intervention type: OTHER
Intervention: No intervention is performed
Description: The study is observational
Study NCT06016296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Movement and Storytelling Intervention
Description: The 40-minute sessions will include three moments: (i) warm-up (5 minutes), which consists of joint mobility exercises and introduction to the motor story of the week; (ii) main part (25 minutes), which incorporates the narration of the motor story by the educator initially, as well as the participation of the children, through their own corporeality with movements based mainly on FMS (locomotion skills and object control) and two way verbal interaction based on questions allusive to the narration delivered by the educator or direct verbal participation cast by each child and; (iii) cool down (10 minutes), where space is provided for the children to gradually return to calm, together with feedback on the contents addressed during the session.
Study NCT05703009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacrosidase Oral Solution
Description: Study drug
Study NCT05703009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06211751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3702 tablets
Description: TQB3702 is a kinase inhibitor.
Study NCT05317663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Test Health Warning Label (HWL)
Description: Effect of Health Warning Label (HWL)
Study NCT05317663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Test without Health Warning Label (no-HWL)
Description: Effect of no Health Warning Label (no-HWL)
Study NCT05496296 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Altrazeal® Transforming Powder Dressing
Description: Pressure injury wounds will be evaluated at each study visit (cleaned, photographed, measured) and a dressing will be applied according to the study arm
Study NCT04945616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin、clopidogrel、placebo or SHR2285
Description: groupA： Aspirin + clopidogrel + placebo or SHR2285 (dose 1) ；
Study NCT04945616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin、clopidogrel、placebo or SHR2285
Description: groupB： Aspirin + clopidogrel + placebo or SHR2285 (dose 2)
Study NCT04945616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin、ticagrelor、placebo or SHR2285
Description: groupC： Aspirin + ticagrelor + placebo or SHR2285
Study NCT06492811 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GAT@F nanoenzyme hydrogel complex
Description: The wound condition was recorded by taking photos each time the dressing was changed. The diabetic wound was routinely treated with a dressing change, after which GAT@F nanoenzyme hydrogel complex was applied externally and a secondary dressing - medical surgical gauze was added. According to existing clinical data, it is recommended to use no more than 10ml per dressing change.
Study NCT06492811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GAT@F nanoenzyme hydrogel complex
Description: The wound condition was recorded by taking photos each time the dressing was changed. The diabetic wound was routinely treated with a dressing change, after which GAT@F nanoenzyme hydrogel complex was applied externally and a secondary dressing - medical surgical gauze was added. According to existing clinical data, it is recommended to use no more than 10ml per dressing change.
Study NCT06492811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GAT@F nanoenzyme hydrogel complex
Description: The wound condition was recorded by taking photos each time the dressing was changed. The diabetic wound was routinely treated with a dressing change, after which GAT@F nanoenzyme hydrogel complex was applied externally and a secondary dressing - medical surgical gauze was added. According to existing clinical data, it is recommended to use no more than 10ml per dressing change.
Study NCT05913921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B liposome for injection
Description: IV infusion, 2.0 mg/kg
Study NCT05913921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AmBisome
Description: IV infusion, 2.0 mg/kg
Study NCT05466019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Toripalimab, FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU)
Description: FLOT: Docetaxel 50mg/m2 ivd d1 + oxaliplatin 85mg/m2 ivd d1 + leucovorin 200mg/m2 ivd d1 + 5-FU 2600mg/m2 civ, Q2W Toripalimab 3mg/kg, intravenously administered on the first day of each cycle, Q2W.
Study NCT05317949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated neuromuscular training program group
Description: Integrated neuromuscular training program group will do plyometric training, speed and sensitivity training, resistance training for 3 days in a week and total for eight weeks.
Study NCT05317949 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General fitness exercises program group
Description: General fitness exercises program group will do general fitness exercise for 3 days in a week and total for eight weeks.
Study NCT05527249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement
Description: 20g of protein powder + 650mg of pomegranate extracts
Study NCT03834909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose Truvada®
Description: TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, one tablet each day
Study NCT03834909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnancy-adjusted dose Truvada®
Description: TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, two tablets each day
Study NCT05527249 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of the dietary supplement
Description: 20g of protein powder + 650mg of maltodextrin
Study NCT05148949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard dosage inactivated vaccine
Description: This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
Study NCT05148949 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard dosage inactivated vaccine
Description: This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
Study NCT05148949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double dosage inactivated vaccine
Description: This vaccine contains 1200 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
Study NCT04865419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0466
Description: AZD0466 powder for concentrate for solution for infusion will be administered by IV infusion.
Study NCT04865419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Voriconazole film-coated tablet will be administered orally.
Study NCT05721521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spin Bike Exercise
Description: 30 minute spin bike class led by a qualified instructor.
Study NCT05721521 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 30 minute completing seated activities (e.g., wordsearches)
Study NCT04747899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positional release technique
Description: Experimental group is given Positional Release Technique along with the hot pack, muscle stretching and posture correction.~Positional release technique position will maintained for almost 90 seconds. This technique will be repeated for three times each session, with 10 sec relaxation, 3 days/week.~Upper trapezius stretching 5 repetitions×1 set, 3 days/ week. Total of 3 sessions were given each consisting of 30 min.~Posture correction in ADLs as well as in working place by advising correct sitting posture, the participants will advised to relieve muscle tension after every 20-30 minutes of work by getting up; stretching the arm, shoulder, neck, and back muscles.
Study NCT05244902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Dextrose
Description: All the patients will receive oral 3mL/kg 5%Dextrose
Study NCT05244902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Dextrose
Description: All the patients will receive oral 3mL/kg 5%Dextrose
Study NCT04536779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training in the local departments of TT and cycling trips with CUA
Description: in a minimum of 3 months, the individuals with low physical mobility will conduct a minimum of 8-10 training and cycling sessions.
Study NCT04855682 — intervention group
Intervention type: OTHER
Intervention: Retrospective observation after 24 months after the spinal procedure
Description: Retrospective evaluation of patients before the procedure, and prospective evaluation of patients 24 months after the spinal procedure, comparing the MRI changes and procedure impact on fatty muscle degeneration process
Study NCT04855682 — intervention group
Intervention type: OTHER
Intervention: Retrospective observation after 12 months after the spinal procedure
Description: Retrospective evaluation of the patient status before the procedure, and prospective evaluation of patients for 12 months after the spinal procedure, comparing the MRI changes
Study NCT04855682 — intervention group
Intervention type: OTHER
Intervention: Prospective evaluation of patients after 12 and 24 months after the spinal procedure
Description: Prospective evaluation of patients after 12 and 24 months after the spinal procedure, comparing the MRI changes
Study NCT04884204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lee Symptom Scala
Description: Symptom identification and management with Lee Symptom Scale in follow up care
Study NCT05375045 — intervention group
Intervention type: DEVICE
Intervention: dental implantation
Description: an implant is surgically inserted into the maxilla or mandible, and then an abutment is connected to this implant to support the dental prosthesis.
Study NCT05151874 — intervention group
Intervention type: DRUG
Intervention: Abobotulinum toxin A
Description: To measure ROM evolution in patients with post-stroke spasticity in the upper limb with spasticity pattern III.
Study NCT05054985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Branched Thoracoabdominal Stent Graft System
Description: Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with multi-branched thoracoabdominal stent graft system .
Study NCT04747899 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy
Description: Hot pack for 15-mins. Upper trapezius stretching 5 repetitions×1 set, 3 days/ week. Total of 3 sessions are given each consisting of 30 min.~Posture correction in ADLs as well as in working place by advising correct sitting posture, the participants will advised to relieve muscle tension after every 20-30 minutes of work by getting up; stretching the arm, shoulder, neck, and back muscles.
Study NCT06025006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alternative to incarceration
Description: place of respite with housing plus intensive follow-up
Study NCT05929287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tablet-based CT
Description: This group will perform digital CT tasks.
Study NCT05929287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paper-and-pencil CT group
Description: This group will perform paper-and-pencil CT tasks.
Study NCT06361589 — intervention group
Intervention type: DRUG
Intervention: Lorlatinib
Description: lolatinib 100mg qd po
Study NCT04930900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARS-1 with URTI
Description: ARS-1
Study NCT04930900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARS-1 without URTI
Description: ARS-1 without URTI